Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
This study highlights the importance of PI3K/Akt in ovarian tumor progression and chemoresistance and the potential application of AZD compounds, especially AZD8835 and AZD5363, as therapeutic agents for the treatment of ovarian cancer.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Epithelial Cancer | Ovarian Cancer | Ovaries | Study